# Immunogenicity
Keywords: PLEGRIDY, immunogenicity, neutralising antibodies, interferons, PEGylation, pharmacokinetics, subcutaneous, intramuscular

> This page provides information about the immunogenicity of PLEGRIDY, highlighting its low rates of neutralising antibodies development, the benefits of PEGylation, and its pharmacokinetic profiles for subcutaneous and intramuscular formulations.

## Details
- [Immunogenicity](#): PLEGRIDY treatment has low rates of immunogenicity, with less than 1% of patients developing persistent neutralising antibodies to interferons over two years.
- [PEGylation](#): PEGylation modifies the pharmacokinetics and pharmacodynamics of interferon alfa, improving safety, tolerability, and reducing immunogenicity.
- [Additional Benefits of PEGylation](#): PLEGRIDY peaks at 24-36 hours post-dose, has a half-life of over three days, and offers bioequivalent subcutaneous and intramuscular formulations.
- [Pharmacokinetic Profiles](#): The pharmacokinetic profiles of PLEGRIDY's subcutaneous and intramuscular formulations are detailed, showing rapid concentration peaks and extended half-life.
- [Adverse Event Reporting](#): Information on how to report adverse events in the UK and Ireland, including contact details for Biogen.